Biogen Idec Initiates Randomized, Registrational Trial Of Lumiliximab For Chronic Lymphocytic Leukemia
Mon, 12 Feb 2007 08:00 AM EST
... Biogen Idec (Nasdaq: BIIB) today announced that it has initiated a randomized, controlled, registration trial of an investigational anti-CD23 monoclonal antibody, lumiliximab, for patients with chronic lymphocytic leukemia (CLL). [click link for full article] ...
Related Topics
- Leukemia, Chronic Lymphocytic
- Chronic Lymphocytic Leukemia
- Leukemia
- Clinical Trials
- Chronic lymphocytic leukemia cancer
- Chronic lymphocytic leukemia (CLL)
- Leukemia, Chronic Myelogenous
- Myelogenous Leukemia, Chronic
- Chronic Myelogenous Leukemia
- Acute Lymphocytic Leukemia (ALL)
- Acute lymphocytic leukemia
- Acute lymphocytic leukemia cancer
- Childhood Leukemia
- Leukemia, Childhood
- Chronic lymphocytic thyroiditis
- Chronic Fatigue Syndrome
- Pain - Chronic
- Chronic Pain
- Chronic Diseases
- Leukemia Chronic

Not Signed In -

